Lung cancer trials in Bulgaria

In Bulgaria 23 Also abroad 2733

23 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Where
Panagyurishte, Pleven, Plovdiv, Sofia
Age
18 years and over
People
348 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00
Phase 3Taking people
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Where
Pleven, Plovdiv, Rousse, Sofia
Age
18 years and over
People
420 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07099898
Phase 3Taking people
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Where
Panagyurishte, Pleven, Sofiya
Age
18 years and over
People
670 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00
Phase 3Taking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Panagyurishte, Pleven, Ruse
Age
18 years and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
Phase 3Taking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Panagyurishte, Pleven, Sofia, Sofiya
Age
18 years to 100 years
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
No phaseTaking people
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Where
Panagyurishte, Rousse, Sofia
Age
18 years and over
People
700 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07284121
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Haskovo, Panagyurishte, Sofia, Sofiya, Stara Zagora
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Haskovo, Ruse, Sofia, Sofiya
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Panagyurishte, Pleven, Plovdiv, Sofia, Sofiya, Varna
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 2/3Taking people
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Where
Sofia
Age
18 years and over
People
750 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00
Phase 2/3Taking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Plovdiv, Ruse, Sofia
Age
18 years and over
People
1,580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Gabrovo, Haskovo, Plovdiv, Sofia
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Burgas, Panagyurishte, Plovdiv, Sofiya, Varna
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Panagyurishte, Ruse, Sofia, Stara Zagora
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 2/3Taking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Haskovo, Ruse, Sofia, Stara Zagora
Age
18 years and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
Phase 3Taking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Ruse, Sofia, Sofiya
Age
18 years and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Haskovo, Plovdiv, Ruse, Vratsa
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 3Taking people
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Where
Gabrovo, Pleven, Plovdiv, Sofia
Age
18 years and over
People
550 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT07625644
Phase 3Taking people
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Where
Burgas, Panagyurishte, Plovdiv, Sofia, Sofiya
Age
18 years and over
People
714 worldwide
Run by
Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
Burgas, Panagyurishte, Sofia, Sofiya
Age
18 years and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
Phase 3Taking people
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Where
Sofia
Age
18 years and over
People
87 worldwide
Run by
Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00
Phase 2Taking people
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Panagyurishte, Pleven
Age
18 years and over
People
204 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00
Phase 1Taking people
A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer
Where
Sofia
Age
18 years and over
People
20 worldwide
Run by
Jiangsu Hansoh Pharmaceutical Co., Ltd.
See details and how to joinNCT07130916